• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

What’s New in Immunotherapy?

by Nikki Kean • October 12, 2020

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Ravindra Uppaluri, MD, PhDIn 10 years, we’ll likely have a much better understanding of what combination therapeutics are most efficacious, understand what biomarkers can stratify patients for immunotherapy, and further develop novel approaches, including cellular therapies and innate immune targeting. —Ravindra Uppaluri, MD, PhD

You Might Also Like

  • New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck
  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • Neoadjuvant Immunotherapy for Skin Cancer
  • Immunotherapy Benefits for Treating Allergic Rhinitis
Explore This Issue
October 2020

Window of Opportunity Trials

Checkpoint inhibitors have changed the practice of treating HNSCC, but even with the positive results, the response rate is still limited to 15% to 20% of patients. “The bottom line is that there continues to be a high need for improved therapy for patients who have locally advanced as well as recurrent or metastatic head and neck disease,” said Maie St. John, MD, PhD, professor and Thomas C. Calcaterra, MD, Chair in Head and Neck Surgery at the University of California, Los Angeles. “It’s a complex balance of immune cell interactions and cell signaling, and we’re trying to harness that to treat our patients.”

Dr. Gourin agreed. “The real challenge ahead is identifying which patients will respond to immunotherapy,” she said. “If we knew this, we could select patients for immunotherapy over conventional treatment with surgery or standard nonsurgical treatment with radiation or chemoradiation.”

© CI Photos / shutterstock.com

© CI Photos / shutterstock.com

That’s why clinical trials of immunotherapy are shifting from treating the sickest patients—those with recurrent or metastatic cancers—to treating earlier stages of cancer, Dr. Uppaluri said. Such a strategy would allow clinicians “to deintensify treatment and decrease collateral damage to normal tissues by giving less radiation, particularly for patients with HPV-positive HNSCC tumors that have a very favorable prognosis,” said Jeffrey Myers, MD, PhD, professor and Alando J. Ballantyne Distinguished Chair of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center in Houston. “There’s some hope, based on the exciting results of ‘window of opportunity’ trials, that in the future we might be able to give a combination of a checkpoint inhibitor and chemotherapy to reduce the size of tumors that could then be treated with lower doses of radiation, thereby improving treatment-related sequalae of high-dose radiation.”

Immunotherapy also has brought a sea change to the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC). Two checkpoint inhibitors are approved by the FDA as first-line systemic therapy for these malignancies: pembrolizumab and cemiplimab (Libtayo, Regeneron). In patients with CSCC, PD-1 blockade with cemiplimab yielded a 49% overall response rate, with a prolonged durable response in the majority of responders, and a 15% incidence of adverse events, “which is a much better [clinical] response than seen with chemotherapy,” said Dr. Gourin (N Engl J Med. 2018;379:341-351).

In addition, the side effect profile appears to be more favorable in patients on immunotherapy compared with patients receiving standard of care: Adverse events occurred in 15% of the immunotherapy patients compared with 35% of patients receiving standard therapy. The results of these trials led to FDA approval of cemiplimab in September 2018 for the treatment of patients with metastatic or locally advanced CSCC.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features, Home Slider Tagged With: clinical research, immunotherapyIssue: October 2020

You Might Also Like:

  • New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck
  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • Neoadjuvant Immunotherapy for Skin Cancer
  • Immunotherapy Benefits for Treating Allergic Rhinitis

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Do you use AI-powered scribes for documentation?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Keeping Watch for Skin Cancers on the Head and Neck

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Excitement Around Gene Therapy for Hearing Restoration

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • The Importance of Time Away
    • Endoscopic Ear Surgery: Advancements and Adoption Challenges 
    • Reflections from a Past President of the Triological Society
    • ENT Surgeons Explore the Benefits and Challenges of AI-Powered Scribes: Revolutionizing Documentation in Healthcare
    • How To: Open Expansion Laryngoplasty for Combined Glottic and Subglottic Stenosis

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939